Skip to main content
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. — Investor Relations & Filings

Ticker · VVOS ISIN · US92859E1082 US Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2025-02-14 Capital/Financing Update
Country US United States of America
Listing US VVOS

About Vivos Therapeutics, Inc.

https://vivos.com/

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company's core offering is The Vivos System, a non-surgical treatment that uses proprietary oral appliances. These devices are designed to address underlying dentofacial abnormalities that can restrict the airway. The treatment protocol aims to promote the natural growth and development of the jaw and airway in both adult and pediatric patients. Vivos provides its technology and training to a network of licensed dentists and medical professionals who deliver the therapy.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement related to an At The Market Offering Agreement for selling common stock, and amendments to employment agreements for key executives. It also includes exhibits such as the offering agreement and employment agreements. There are no financial statements or detailed financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy statement, earnings release, or call transcript. The primary focus is on a financing agreement and management employment agreements, which fits best under Capital/Financing Update (CAP) for the offering agreement and Board/Management Information (MANG) for the employment agreements. However, since the document is a single 8-K filing covering both, and the main headline and majority content is about the At The Market Offering Agreement, the best classification is Capital/Financing Update (CAP). Confidence is high because the document is a Form 8-K with a material definitive agreement about stock offering, which is a classic CAP filing.
2025-02-14 English
Regulatory Filings 2025
Regulatory Filings
2025-02-13 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering. It includes a prospectus describing the securities to be offered, the terms of the offering, and related legal and financial information. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement or a brief notice.
2025-02-11 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for the offer and sale of common stock and warrants by Vivos Therapeutics, Inc. It includes information about the securities being offered, the use of proceeds, risk factors, business overview, management discussion, executive compensation, and legal matters. The presence of terms like 'prospectus', 'offering', 'shares', 'warrants', and detailed descriptions of the securities and selling stockholders clearly indicate this is a capital raising document. It is not a financial report, earnings release, or management discussion report. It is not an announcement or notice but the actual offering document. Therefore, the document fits the category of Capital/Financing Update (CAP).
2025-01-31 English
Regulatory Filings 2025
Regulatory Filings
2025-01-31 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter from the CFO of Vivos Therapeutics, Inc. to the SEC requesting acceleration of effectiveness of a Registration Statement on Form S-1. This is related to a securities offering process and is a regulatory communication rather than a financial report or earnings release. The document is short (929 characters) and is a formal regulatory filing related to securities registration, not a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS).
2025-01-29 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.